Visilizumab, a novel engineered immunoglobulin , exhibits a unique process of action targeting specifically the sIg9 receptor present on granulocytes . This attachment leads to a reduction in granulocyte activation , ultimately dampening inflammatory responses during acute tissue injury . The med